# DESCRIPTION

## BACKGROUND

- introduce HIV/AIDS and cART
- describe HIV-capsid as antiviral target
- detail CA protein structure and function
- discuss CA's role in viral replication
- describe CA inhibitors and their effects
- highlight need for new antivirals
- introduce GS-CA1 and GS-6207

## SUMMARY

- introduce cyclic or linear peptide
- describe peptide sequence and variations
- detail peptide binding to HIV-1 capsid protein
- describe peptide properties and activities
- outline pharmaceutical composition and method of treatment

## DETAILED DESCRIPTION

### Definitions

- define "a" or "an" entity
- define "and/or"
- define "comprising"
- define technical and scientific terms
- define numeric ranges
- define headings
- define "polypeptide"
- define "cyclic peptide"
- define "polar uncharged amino acid"
- define "hydrophobic amino acid"
- define "protein"
- define "isolated" polypeptide or fragment

### Overview

- introduce GS-CA1-bound CA hexamer structure
- compare GS-CA1 with PF74, CPSF6, and NUP153
- describe GS-CA1 interactions with CA hexamer
- analyze GS-CA1 resistance mutations
- discuss GS-6207 modifications and binding affinity
- compare GS-6207 with GS-CA1 and PF74
- analyze K70 side chain conformation in CA/GS-6207 complex
- compare GS-CA1 with PF74 and BI-2 crystal structures
- identify common resistance mutations between GS-CA1 and PF74
- analyze GS-CA1 binding mode with CA-hexamer
- compare GS-CA1 with CPSF6 and NUP153 crystal structures
- identify common structural features among GS-CA1, CPSF6, and NUP153
- compare GS-CA1 with CA/CAP-1, CA/BD, and CA/BM complexes
- analyze Coumermycin A1 binding to CA-hexamers
- discuss other small molecule inhibitors of CA
- design and dock a cyclic peptide inhibitor (Pep-2-cyclic)
- determine binding affinity of CA with Pep-2-cyclic and PF74

### Cyclic Peptides

- define cyclic peptide sequence
- specify X1, X2, X3 variations
- describe additional amino acids
- specify length of cyclic peptide
- describe optional dye, chelator, radionuclide
- specify binding to HIV-1 capsid protein
- describe binding affinity and inhibitory activity
- describe method of producing cyclic peptide

### Linear Peptides

- define linear peptide sequence
- specify X1, X2, X3 variations
- describe additional amino acids
- specify length of linear peptide
- describe optional C-terminal acid or amide
- describe optional dye, chelator, radionuclide
- specify binding to HIV-1 capsid protein
- describe binding affinity and inhibitory activity
- describe method of producing linear peptide

## EXAMPLES

### Example 1

- prepare HIV-1 CA structure for docking

### Example 2

- perform docking simulations of GS-CA1, GS-6207, and CA-1

### Example 3

- perform docking simulations of designed peptide Pep-2-Cyclic

### Example 4

- synthesize peptide Pep-2-cyclic
- label CA with Alexa Fluor 647
- perform MST assays
- analyze MST data
- determine binding affinities
- calculate Kd values
- plot binding curves
- compare binding affinities
- discuss results

